Metformin Hydrochloride Dhp Healthcare (Metformin Hydrochloride)

The drug activates AMP‑activated protein kinase (AMPK), which suppresses liver glucose output, decreases intestinal glucose absorption, and enhances peripheral uptake of glucose, thereby improving overall glycemic control.

The dosage of Metformin Hydrochloride is individualized by the prescribing clinician based on the patient’s renal function, glycemic targets, and tolerability. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of Metformin Hydrochloride in pregnancy and lactation has not been definitively established. Healthcare providers weigh potential benefits against possible risks before prescribing to pregnant or nursing women.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Metformin belongs to the biguanide class and is often preferred as first‑line therapy because it does not cause weight gain and has a low risk of hypoglycemia compared with sulfonylureas or insulin. Its mechanism differs from thiazolidinediones, which act primarily on adipose tissue.

Store the tablets at ambient temperature below 25 °C, in the original packaging, and protect them from moisture and direct sunlight. Do not refrigerate or freeze the product.

Metformin Hydrochloride is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious adverse effect is lactic acidosis, a rare but potentially fatal condition. Risk increases in patients with severe renal impairment, hepatic disease, heart failure, or excessive alcohol consumption.

Metformin is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, and those receiving iodinated contrast agents without appropriate renal monitoring.